ALL (Acute Lymphoblastic Leukemia),Leukemia Improved Outcomes in High-Risk Relapsed B-ALL with Blinatumomab Feb 27, 2023
CLL (Chronic Lymphocytic Leukemia),Leukemia,Lymphoma Comparing Relapsed or Refractory CLL with Zanubrutinib and Ibrutnib Phase 3 Trial Feb 16, 2023